APO Research
Talk to an analyst

APO RESEARCH · REPORT

Spinal Muscular Atrophy Medicine

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Spinal Muscular Atrophy Medicine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

26 December 2025198 pages

Choose your research edition.

Industry ResearchSpinal Muscular Atrophy Medicine Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal Spinal Muscular Atrophy Medicine Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Spinal Muscular Atrophy Medicine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Spinal Muscular Atrophy Medicine Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Spinal Muscular Atrophy Medicine Market Analysis and Forecast 2026-2032203 pages · $4,950 USD

Market perspective

The global Spinal Muscular Atrophy Medicine market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Spinal Muscular Atrophy Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Spinal Muscular Atrophy Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Spinal Muscular Atrophy Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Spinal Muscular Atrophy Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Spinal Muscular Atrophy Medicine include Novartis AG, Astellas Pharma Inc., WAVE Life Sciences Ltd., Vybion, Inc., Voyager Therapeutics, Inc., Sarepta Therapeutics, Inc., Neurotune AG, Neurodyn Inc. and Longevity Biotech, Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Spinal Muscular Atrophy Medicine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Spinal Muscular Atrophy Medicine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Spinal Muscular Atrophy Medicine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Spinal Muscular Atrophy Medicine market size, projected growth trends, production technologies, key applications, and end-use industries.

Spinal Muscular Atrophy Medicine Segment by Company

Novartis AG

Astellas Pharma Inc.

WAVE Life Sciences Ltd.

Vybion, Inc.

Voyager Therapeutics, Inc.

Sarepta Therapeutics, Inc.

Neurotune AG

Neurodyn Inc.

Longevity Biotech, Inc

Ionis Pharmaceuticals, Inc.

GMP-Orphan SAS

Genzyme Corporation

Genethon

F. Hoffmann-La Roche Ltd.

Cytokinetics, Inc. 24

Bioblast Pharma Ltd.

AveXis, Inc.

Spinal Muscular Atrophy Medicine Segment by Type

LMI-070

ND-602

NT-1654

NXD-30001

Nusinersen

Others

Spinal Muscular Atrophy Medicine Segment by Application

Hospital

Clinic

Others

Spinal Muscular Atrophy Medicine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Spinal Muscular Atrophy Medicine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Spinal Muscular Atrophy Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Spinal Muscular Atrophy Medicine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Spinal Muscular Atrophy Medicine market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Spinal Muscular Atrophy Medicine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Spinal Muscular Atrophy Medicine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Spinal Muscular Atrophy Medicine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Spinal Muscular Atrophy Medicine Industry Trends Table 2. Spinal Muscular Atrophy Medicine Industry Drivers Table 3. Spinal Muscular Atrophy Medicine Industry Opportunities and Challenges Table 4. Spinal Muscular Atrophy Medicine Industry Restraints Table 5. Global Spinal Muscular Atrophy Medicine Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Spinal Muscular Atrophy Medicine Sales by Manufacturers (W Units) & (2021-2026) Table 8. Global Spinal Muscular Atrophy Medicine Sales Market Share by Manufacturers Table 9. Global Spinal Muscular Atrophy Medicine Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Spinal Muscular Atrophy Medicine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Spinal Muscular Atrophy Medicine Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Spinal Muscular Atrophy Medicine Manufacturers, Product Type & Application Table 13. Global Spinal Muscular Atrophy Medicine Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Spinal Muscular Atrophy Medicine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of LMI-070 Table 17. Major Manufacturers of ND-602 Table 18. Major Manufacturers of NT-1654 Table 19. Major Manufacturers of NXD-30001 Table 20. Major Manufacturers of Nusinersen Table 21. Major Manufacturers of Others Table 22. Global Spinal Muscular Atrophy Medicine Sales by Type 2021 VS 2025 VS 2032 (W Units) Table 23. Global Spinal Muscular Atrophy Medicine Sales by Type (2021-2026) & (W Units) Table 24. Global Spinal Muscular Atrophy Medicine Sales by Type (2027-2032) & (W Units) Table 25. Global Spinal Muscular Atrophy Medicine Sales Market Share by Type (2021-2026) Table 26. Global Spinal Muscular Atrophy Medicine Sales Market Share by Type (2027-2032) Table 27. Global Spinal Muscular Atrophy Medicine Revenue by Type 2021 VS 2025 VS 2032 (W Units) Table 28. Global Spinal Muscular Atrophy Medicine Revenue by Type (2021-2026) & (W Units) Table 29. Global Spinal Muscular Atrophy Medicine Revenue by Type (2027-2032) & (W Units) Table 30. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Type (2021-2026) Table 31. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Type (2027-2032) Table 32. Major Manufacturers of Hospital Table 33. Major Manufacturers of Clinic Table 34. Major Manufacturers of Others Table 35. Global Spinal Muscular Atrophy Medicine Sales by Application 2021 VS 2025 VS 2032 (W Units) Table 36. Global Spinal Muscular Atrophy Medicine Sales by Application (2021-2026) & (W Units) Table 37. Global Spinal Muscular Atrophy Medicine Sales by Application (2027-2032) & (W Units) Table 38. Global Spinal Muscular Atrophy Medicine Sales Market Share by Application (2021-2026) Table 39. Global Spinal Muscular Atrophy Medicine Sales Market Share by Application (2027-2032) Table 40. Global Spinal Muscular Atrophy Medicine Revenue by Application 2021 VS 2025 VS 2032 (W Units) Table 41. Global Spinal Muscular Atrophy Medicine Revenue by Application (2021-2026) & (W Units) Table 42. Global Spinal Muscular Atrophy Medicine Revenue by Application (2027-2032) & (W Units) Table 43. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Application (2021-2026) Table 44. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Application (2027-2032) Table 45. Global Spinal Muscular Atrophy Medicine Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 46. Global Spinal Muscular Atrophy Medicine Sales by Region (2021-2026) & (W Units) Table 47. Global Spinal Muscular Atrophy Medicine Sales Market Share by Region (2021-2026) Table 48. Global Spinal Muscular Atrophy Medicine Sales Forecasted by Region (2027-2032) & (W Units) Table 49. Global Spinal Muscular Atrophy Medicine Sales Forecasted Market Share by Region (2027-2032) Table 50. North America Spinal Muscular Atrophy Medicine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 51. North America Spinal Muscular Atrophy Medicine Sales by Country (2021-2026) & (W Units) Table 52. North America Spinal Muscular Atrophy Medicine Sales by Country (2027-2032) & (W Units) Table 53. Europe Spinal Muscular Atrophy Medicine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 54. Europe Spinal Muscular Atrophy Medicine Sales by Country (2021-2026) & (W Units) Table 55. Europe Spinal Muscular Atrophy Medicine Sales by Country (2027-2032) & (W Units) Table 56. Asia Pacific Spinal Muscular Atrophy Medicine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 57. Asia Pacific Spinal Muscular Atrophy Medicine Sales by Country (2021-2026) & (W Units) Table 58. Asia Pacific Spinal Muscular Atrophy Medicine Sales by Country (2027-2032) & (W Units) Table 59. South America, Middle East and Africa Spinal Muscular Atrophy Medicine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 60. South America, Middle East and Africa Spinal Muscular Atrophy Medicine Sales by Country (2021-2026) & (W Units) Table 61. South America, Middle East and Africa Spinal Muscular Atrophy Medicine Sales by Country (2027-2032) & (W Units) Table 62. Global Spinal Muscular Atrophy Medicine Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Global Spinal Muscular Atrophy Medicine Revenue by Region (2021-2026) & (US$ Million) Table 64. Global Spinal Muscular Atrophy Medicine Revenue by Region (2027-2032) & (US$ Million) Table 65. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Region (2021-2026) Table 66. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Region (2027-2032) Table 67. Novartis AG Company Information Table 68. Novartis AG Business Overview Table 69. Novartis AG Spinal Muscular Atrophy Medicine Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Novartis AG Spinal Muscular Atrophy Medicine Product Portfolio Table 71. Novartis AG Recent Development Table 72. Astellas Pharma Inc. Company Information Table 73. Astellas Pharma Inc. Business Overview Table 74. Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Product Portfolio Table 76. Astellas Pharma Inc. Recent Development Table 77. WAVE Life Sciences Ltd. Company Information Table 78. WAVE Life Sciences Ltd. Business Overview Table 79. WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Product Portfolio Table 81. WAVE Life Sciences Ltd. Recent Development Table 82. Vybion, Inc. Company Information Table 83. Vybion, Inc. Business Overview Table 84. Vybion, Inc. Spinal Muscular Atrophy Medicine Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Vybion, Inc. Spinal Muscular Atrophy Medicine Product Portfolio Table 86. Vybion, Inc. Recent Development Table 87. Voyager Therapeutics, Inc. Company Information Table 88. Voyager Therapeutics, Inc. Business Overview Table 89. Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Portfolio Table 91. Voyager Therapeutics, Inc. Recent Development Table 92. Sarepta Therapeutics, Inc. Company Information Table 93. Sarepta Therapeutics, Inc. Business Overview Table 94. Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Portfolio Table 96. Sarepta Therapeutics, Inc. Recent Development Table 97. Neurotune AG Company Information Table 98. Neurotune AG Business Overview Table 99. Neurotune AG Spinal Muscular Atrophy Medicine Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. Neurotune AG Spinal Muscular Atrophy Medicine Product Portfolio Table 101. Neurotune AG Recent Development Table 102. Neurodyn Inc. Company Information Table 103. Neurodyn Inc. Business Overview Table 104. Neurodyn Inc. Spinal Muscular Atrophy Medicine Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. Neurodyn Inc. Spinal Muscular Atrophy Medicine Product Portfolio Table 106. Neurodyn Inc. Recent Development Table 107. Longevity Biotech, Inc Company Information Table 108. Longevity Biotech, Inc Business Overview Table 109. Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Product Portfolio Table 111. Longevity Biotech, Inc Recent Development Table 112. Ionis Pharmaceuticals, Inc. Company Information Table 113. Ionis Pharmaceuticals, Inc. Business Overview Table 114. Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 115. Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Product Portfolio Table 116. Ionis Pharmaceuticals, Inc. Recent Development Table 117. GMP-Orphan SAS Company Information Table 118. GMP-Orphan SAS Business Overview Table 119. GMP-Orphan SAS Spinal Muscular Atrophy Medicine Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 120. GMP-Orphan SAS Spinal Muscular Atrophy Medicine Product Portfolio Table 121. GMP-Orphan SAS Recent Development Table 122. Genzyme Corporation Company Information Table 123. Genzyme Corporation Business Overview Table 124. Genzyme Corporation Spinal Muscular Atrophy Medicine Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 125. Genzyme Corporation Spinal Muscular Atrophy Medicine Product Portfolio Table 126. Genzyme Corporation Recent Development Table 127. Genethon Company Information Table 128. Genethon Business Overview Table 129. Genethon Spinal Muscular Atrophy Medicine Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 130. Genethon Spinal Muscular Atrophy Medicine Product Portfolio Table 131. Genethon Recent Development Table 132. F. Hoffmann-La Roche Ltd. Company Information Table 133. F. Hoffmann-La Roche Ltd. Business Overview Table 134. F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 135. F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Product Portfolio Table 136. F. Hoffmann-La Roche Ltd. Recent Development Table 137. Cytokinetics, Inc. 24 Company Information Table 138. Cytokinetics, Inc. 24 Business Overview Table 139. Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 140. Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Product Portfolio Table 141. Cytokinetics, Inc. 24 Recent Development Table 142. Bioblast Pharma Ltd. Company Information Table 143. Bioblast Pharma Ltd. Business Overview Table 144. Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 145. Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Product Portfolio Table 146. Bioblast Pharma Ltd. Recent Development Table 147. AveXis, Inc. Company Information Table 148. AveXis, Inc. Business Overview Table 149. AveXis, Inc. Spinal Muscular Atrophy Medicine Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 150. AveXis, Inc. Spinal Muscular Atrophy Medicine Product Portfolio Table 151. AveXis, Inc. Recent Development Table 152. Key Raw Materials Table 153. Raw Materials Key Suppliers Table 154. Spinal Muscular Atrophy Medicine Distributors List Table 155. Spinal Muscular Atrophy Medicine Customers List Table 156. Research Programs/Design for This Report Table 157. Authors List of This Report Table 158. Secondary Sources Table 159. Primary Sources List of Figures Figure 1. Spinal Muscular Atrophy Medicine Product Image Figure 2. Global Spinal Muscular Atrophy Medicine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Spinal Muscular Atrophy Medicine Market Size (2021-2032) & (US$ Million) Figure 4. Global Spinal Muscular Atrophy Medicine Sales (2021-2032) & (W Units) Figure 5. Global Spinal Muscular Atrophy Medicine Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Spinal Muscular Atrophy Medicine Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. LMI-070 Image Figure 9. ND-602 Image Figure 10. NT-1654 Image Figure 11. NXD-30001 Image Figure 12. Nusinersen Image Figure 13. Others Image Figure 14. Global Spinal Muscular Atrophy Medicine Sales by Type (2021 VS 2025 VS 2032) & (W Units) Figure 15. Global Spinal Muscular Atrophy Medicine Sales Market Share 2021 VS 2025 VS 2032 Figure 16. Global Spinal Muscular Atrophy Medicine Sales Market Share by Type (2021-2032) Figure 17. Global Spinal Muscular Atrophy Medicine Revenue by Type (2021 VS 2025 VS 2032) & (W Units) Figure 18. Global Spinal Muscular Atrophy Medicine Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Type (2021-2032) Figure 20. Hospital Image Figure 21. Clinic Image Figure 22. Others Image Figure 23. Global Spinal Muscular Atrophy Medicine Sales by Application (2021 VS 2025 VS 2032) & (W Units) Figure 24. Global Spinal Muscular Atrophy Medicine Sales Market Share 2021 VS 2025 VS 2032 Figure 25. Global Spinal Muscular Atrophy Medicine Sales Market Share by Application (2021-2032) Figure 26. Global Spinal Muscular Atrophy Medicine Revenue by Application (2021 VS 2025 VS 2032) & (W Units) Figure 27. Global Spinal Muscular Atrophy Medicine Revenue Market Share 2021 VS 2025 VS 2032 Figure 28. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Application (2021-2032) Figure 29. North America Spinal Muscular Atrophy Medicine Sales and Growth Rate (2021-2032) & (W Units) Figure 30. North America Spinal Muscular Atrophy Medicine Sales Market Share by Country (2021-2032) Figure 31. U.S. Spinal Muscular Atrophy Medicine Sales and Growth Rate (2021-2032) & (W Units) Figure 32. Canada Spinal Muscular Atrophy Medicine Sales and Growth Rate (2021-2032) & (W Units) Figure 33. Mexico Spinal Muscular Atrophy Medicine Sales and Growth Rate (2021-2032) & (W Units) Figure 34. Europe Spinal Muscular Atrophy Medicine Sales and Growth Rate (2021-2032) & (W Units) Figure 35. Europe Spinal Muscular Atrophy Medicine Sales Market Share by Country (2021-2032) Figure 36. Germany Spinal Muscular Atrophy Medicine Sales and Growth Rate (2021-2032) & (W Units) Figure 37. France Spinal Muscular Atrophy Medicine Sales and Growth Rate (2021-2032) & (W Units) Figure 38. U.K. Spinal Muscular Atrophy Medicine Sales and Growth Rate (2021-2032) & (W Units) Figure 39. Italy Spinal Muscular Atrophy Medicine Sales and Growth Rate (2021-2032) & (W Units) Figure 40. Netherlands Spinal Muscular Atrophy Medicine Sales and Growth Rate (2021-2032) & (W Units) Figure 41. Asia Pacific Spinal Muscular Atrophy Medicine Sales and Growth Rate (2021-2032) & (W Units) Figure 42. Asia Pacific Spinal Muscular Atrophy Medicine Sales Market Share by Country (2021-2032) Figure 43. China Spinal Muscular Atrophy Medicine Sales and Growth Rate (2021-2032) & (W Units) Figure 44. Japan Spinal Muscular Atrophy Medicine Sales and Growth Rate (2021-2032) & (W Units) Figure 45. South Korea Spinal Muscular Atrophy Medicine Sales and Growth Rate (2021-2032) & (W Units) Figure 46. Southeast Asia Spinal Muscular Atrophy Medicine Sales and Growth Rate (2021-2032) & (W Units) Figure 47. India Spinal Muscular Atrophy Medicine Sales and Growth Rate (2021-2032) & (W Units) Figure 48. Australia Spinal Muscular Atrophy Medicine Sales and Growth Rate (2021-2032) & (W Units) Figure 49. South America, Middle East and Africa Spinal Muscular Atrophy Medicine Sales and Growth Rate (2021-2032) & (W Units) Figure 50. South America, Middle East and Africa Spinal Muscular Atrophy Medicine Sales Market Share by Country (2021-2032) Figure 51. Brazil Spinal Muscular Atrophy Medicine Sales and Growth Rate (2021-2032) & (W Units) Figure 52. South Africa Spinal Muscular Atrophy Medicine Sales and Growth Rate (2021-2032) & (W Units) Figure 53. Saudi Arabia Spinal Muscular Atrophy Medicine Sales and Growth Rate (2021-2032) & (W Units) Figure 54. Turkey Spinal Muscular Atrophy Medicine Sales and Growth Rate (2021-2032) & (W Units) Figure 55. Argentina Spinal Muscular Atrophy Medicine Sales and Growth Rate (2021-2032) & (W Units) Figure 56. UAE Spinal Muscular Atrophy Medicine Sales and Growth Rate (2021-2032) & (W Units) Figure 57. Egypt Spinal Muscular Atrophy Medicine Sales and Growth Rate (2021-2032) & (W Units) Figure 58. Chile Spinal Muscular Atrophy Medicine Sales and Growth Rate (2021-2032) & (W Units) Figure 59. Global Spinal Muscular Atrophy Medicine Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 61. North America Spinal Muscular Atrophy Medicine Revenue (2021-2032) & (US$ Million) Figure 62. North America Spinal Muscular Atrophy Medicine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Europe Spinal Muscular Atrophy Medicine Revenue (2021-2032) & (US$ Million) Figure 64. Europe Spinal Muscular Atrophy Medicine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Asia-Pacific Spinal Muscular Atrophy Medicine Revenue (2021-2032) & (US$ Million) Figure 66. Asia-Pacific Spinal Muscular Atrophy Medicine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. South America, Middle East and Africa Spinal Muscular Atrophy Medicine Revenue (2021-2032) & (US$ Million) Figure 68. South America, Middle East and Africa Spinal Muscular Atrophy Medicine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. Spinal Muscular Atrophy Medicine Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Spinal Muscular Atrophy Medicine Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • LMI-070
  • ND-602
  • NT-1654
  • NXD-30001
  • Nusinersen
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Novartis AG
  • Astellas Pharma Inc.
  • WAVE Life Sciences Ltd.
  • Vybion, Inc.
  • Voyager Therapeutics, Inc.
  • Sarepta Therapeutics, Inc.
  • Neurotune AG
  • Neurodyn Inc.
  • Longevity Biotech, Inc
  • Ionis Pharmaceuticals, Inc.
  • GMP-Orphan SAS
  • Genzyme Corporation
  • Genethon
  • F. Hoffmann-La Roche Ltd.
  • Cytokinetics, Inc. 24
  • Bioblast Pharma Ltd.
  • AveXis, Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Spinal Muscular Atrophy Medicine Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Spinal Muscular Atrophy Medicine Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Spinal Muscular Atrophy Medicine Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Spinal Muscular Atrophy Medicine Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Spinal Muscular Atrophy Medicine Market Dynamics
  1. 2.1 Spinal Muscular Atrophy Medicine Industry Trends
  2. 2.2 Spinal Muscular Atrophy Medicine Industry Drivers
  3. 2.3 Spinal Muscular Atrophy Medicine Industry Opportunities and Challenges
  4. 2.4 Spinal Muscular Atrophy Medicine Industry Restraints
3 Spinal Muscular Atrophy Medicine Market by Manufacturers
  1. 3.1 Global Spinal Muscular Atrophy Medicine Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Spinal Muscular Atrophy Medicine Sales by Manufacturers (2021-2026)
  3. 3.3 Global Spinal Muscular Atrophy Medicine Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Spinal Muscular Atrophy Medicine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Spinal Muscular Atrophy Medicine Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Spinal Muscular Atrophy Medicine Manufacturers, Product Type & Application
  7. 3.7 Global Spinal Muscular Atrophy Medicine Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Spinal Muscular Atrophy Medicine Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Spinal Muscular Atrophy Medicine Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Spinal Muscular Atrophy Medicine Tier 1, Tier 2, and Tier 3
4 Spinal Muscular Atrophy Medicine Market by Type
  1. 4.1 Spinal Muscular Atrophy Medicine Type Introduction
  2. 4.1.1 LMI-070
  3. 4.1.2 ND-602
  4. 4.1.3 NT-1654
  5. 4.1.4 NXD-30001
  6. 4.1.5 Nusinersen
  7. 4.1.6 Others
  8. 4.2 Global Spinal Muscular Atrophy Medicine Sales by Type
  9. 4.2.1 Global Spinal Muscular Atrophy Medicine Sales by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Spinal Muscular Atrophy Medicine Sales by Type (2021-2032)
  11. 4.2.3 Global Spinal Muscular Atrophy Medicine Sales Market Share by Type (2021-2032)
  12. 4.3 Global Spinal Muscular Atrophy Medicine Revenue by Type
  13. 4.3.1 Global Spinal Muscular Atrophy Medicine Revenue by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Spinal Muscular Atrophy Medicine Revenue by Type (2021-2032)
  15. 4.3.3 Global Spinal Muscular Atrophy Medicine Revenue Market Share by Type (2021-2032)
5 Spinal Muscular Atrophy Medicine Market by Application
  1. 5.1 Spinal Muscular Atrophy Medicine Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Spinal Muscular Atrophy Medicine Sales by Application
  6. 5.2.1 Global Spinal Muscular Atrophy Medicine Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Spinal Muscular Atrophy Medicine Sales by Application (2021-2032)
  8. 5.2.3 Global Spinal Muscular Atrophy Medicine Sales Market Share by Application (2021-2032)
  9. 5.3 Global Spinal Muscular Atrophy Medicine Revenue by Application
  10. 5.3.1 Global Spinal Muscular Atrophy Medicine Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Spinal Muscular Atrophy Medicine Revenue by Application (2021-2032)
  12. 5.3.3 Global Spinal Muscular Atrophy Medicine Revenue Market Share by Application (2021-2032)
6 Global Spinal Muscular Atrophy Medicine Sales by Region
  1. 6.1 Global Spinal Muscular Atrophy Medicine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Spinal Muscular Atrophy Medicine Sales by Region (2021-2032)
  3. 6.2.1 Global Spinal Muscular Atrophy Medicine Sales by Region (2021-2026)
  4. 6.2.2 Global Spinal Muscular Atrophy Medicine Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Spinal Muscular Atrophy Medicine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Spinal Muscular Atrophy Medicine Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Spinal Muscular Atrophy Medicine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Spinal Muscular Atrophy Medicine Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Spinal Muscular Atrophy Medicine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Spinal Muscular Atrophy Medicine Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Spinal Muscular Atrophy Medicine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Spinal Muscular Atrophy Medicine Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Spinal Muscular Atrophy Medicine Revenue by Region
  1. 7.1 Global Spinal Muscular Atrophy Medicine Revenue by Region
  2. 7.1.1 Global Spinal Muscular Atrophy Medicine Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Spinal Muscular Atrophy Medicine Revenue by Region (2021-2026)
  4. 7.1.3 Global Spinal Muscular Atrophy Medicine Revenue by Region (2027-2032)
  5. 7.1.4 Global Spinal Muscular Atrophy Medicine Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Spinal Muscular Atrophy Medicine Revenue (2021-2032)
  8. 7.2.2 North America Spinal Muscular Atrophy Medicine Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Spinal Muscular Atrophy Medicine Revenue (2021-2032)
  11. 7.3.2 Europe Spinal Muscular Atrophy Medicine Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Spinal Muscular Atrophy Medicine Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Spinal Muscular Atrophy Medicine Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Spinal Muscular Atrophy Medicine Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Spinal Muscular Atrophy Medicine Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis AG
  2. 8.1.1 Novartis AG Company Information
  3. 8.1.2 Novartis AG Business Overview
  4. 8.1.3 Novartis AG Spinal Muscular Atrophy Medicine Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Novartis AG Spinal Muscular Atrophy Medicine Product Portfolio
  6. 8.1.5 Novartis AG Recent Developments
  7. 8.2 Astellas Pharma Inc.
  8. 8.2.1 Astellas Pharma Inc. Company Information
  9. 8.2.2 Astellas Pharma Inc. Business Overview
  10. 8.2.3 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Product Portfolio
  12. 8.2.5 Astellas Pharma Inc. Recent Developments
  13. 8.3 WAVE Life Sciences Ltd.
  14. 8.3.1 WAVE Life Sciences Ltd. Company Information
  15. 8.3.2 WAVE Life Sciences Ltd. Business Overview
  16. 8.3.3 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Product Portfolio
  18. 8.3.5 WAVE Life Sciences Ltd. Recent Developments
  19. 8.4 Vybion, Inc.
  20. 8.4.1 Vybion, Inc. Company Information
  21. 8.4.2 Vybion, Inc. Business Overview
  22. 8.4.3 Vybion, Inc. Spinal Muscular Atrophy Medicine Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Vybion, Inc. Spinal Muscular Atrophy Medicine Product Portfolio
  24. 8.4.5 Vybion, Inc. Recent Developments
  25. 8.5 Voyager Therapeutics, Inc.
  26. 8.5.1 Voyager Therapeutics, Inc. Company Information
  27. 8.5.2 Voyager Therapeutics, Inc. Business Overview
  28. 8.5.3 Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Portfolio
  30. 8.5.5 Voyager Therapeutics, Inc. Recent Developments
  31. 8.6 Sarepta Therapeutics, Inc.
  32. 8.6.1 Sarepta Therapeutics, Inc. Company Information
  33. 8.6.2 Sarepta Therapeutics, Inc. Business Overview
  34. 8.6.3 Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Portfolio
  36. 8.6.5 Sarepta Therapeutics, Inc. Recent Developments
  37. 8.7 Neurotune AG
  38. 8.7.1 Neurotune AG Company Information
  39. 8.7.2 Neurotune AG Business Overview
  40. 8.7.3 Neurotune AG Spinal Muscular Atrophy Medicine Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Neurotune AG Spinal Muscular Atrophy Medicine Product Portfolio
  42. 8.7.5 Neurotune AG Recent Developments
  43. 8.8 Neurodyn Inc.
  44. 8.8.1 Neurodyn Inc. Company Information
  45. 8.8.2 Neurodyn Inc. Business Overview
  46. 8.8.3 Neurodyn Inc. Spinal Muscular Atrophy Medicine Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Neurodyn Inc. Spinal Muscular Atrophy Medicine Product Portfolio
  48. 8.8.5 Neurodyn Inc. Recent Developments
  49. 8.9 Longevity Biotech, Inc
  50. 8.9.1 Longevity Biotech, Inc Company Information
  51. 8.9.2 Longevity Biotech, Inc Business Overview
  52. 8.9.3 Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Product Portfolio
  54. 8.9.5 Longevity Biotech, Inc Recent Developments
  55. 8.10 Ionis Pharmaceuticals, Inc.
  56. 8.10.1 Ionis Pharmaceuticals, Inc. Company Information
  57. 8.10.2 Ionis Pharmaceuticals, Inc. Business Overview
  58. 8.10.3 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Product Portfolio
  60. 8.10.5 Ionis Pharmaceuticals, Inc. Recent Developments
  61. 8.11 GMP-Orphan SAS
  62. 8.11.1 GMP-Orphan SAS Company Information
  63. 8.11.2 GMP-Orphan SAS Business Overview
  64. 8.11.3 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Product Portfolio
  66. 8.11.5 GMP-Orphan SAS Recent Developments
  67. 8.12 Genzyme Corporation
  68. 8.12.1 Genzyme Corporation Company Information
  69. 8.12.2 Genzyme Corporation Business Overview
  70. 8.12.3 Genzyme Corporation Spinal Muscular Atrophy Medicine Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Genzyme Corporation Spinal Muscular Atrophy Medicine Product Portfolio
  72. 8.12.5 Genzyme Corporation Recent Developments
  73. 8.13 Genethon
  74. 8.13.1 Genethon Company Information
  75. 8.13.2 Genethon Business Overview
  76. 8.13.3 Genethon Spinal Muscular Atrophy Medicine Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Genethon Spinal Muscular Atrophy Medicine Product Portfolio
  78. 8.13.5 Genethon Recent Developments
  79. 8.14 F. Hoffmann-La Roche Ltd.
  80. 8.14.1 F. Hoffmann-La Roche Ltd. Company Information
  81. 8.14.2 F. Hoffmann-La Roche Ltd. Business Overview
  82. 8.14.3 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Product Portfolio
  84. 8.14.5 F. Hoffmann-La Roche Ltd. Recent Developments
  85. 8.15 Cytokinetics, Inc. 24
  86. 8.15.1 Cytokinetics, Inc. 24 Company Information
  87. 8.15.2 Cytokinetics, Inc. 24 Business Overview
  88. 8.15.3 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Product Portfolio
  90. 8.15.5 Cytokinetics, Inc. 24 Recent Developments
  91. 8.16 Bioblast Pharma Ltd.
  92. 8.16.1 Bioblast Pharma Ltd. Company Information
  93. 8.16.2 Bioblast Pharma Ltd. Business Overview
  94. 8.16.3 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Product Portfolio
  96. 8.16.5 Bioblast Pharma Ltd. Recent Developments
  97. 8.17 AveXis, Inc.
  98. 8.17.1 AveXis, Inc. Company Information
  99. 8.17.2 AveXis, Inc. Business Overview
  100. 8.17.3 AveXis, Inc. Spinal Muscular Atrophy Medicine Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 AveXis, Inc. Spinal Muscular Atrophy Medicine Product Portfolio
  102. 8.17.5 AveXis, Inc. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Spinal Muscular Atrophy Medicine Value Chain Analysis
  2. 9.1.1 Spinal Muscular Atrophy Medicine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Spinal Muscular Atrophy Medicine Production Mode & Process
  6. 9.2 Spinal Muscular Atrophy Medicine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Spinal Muscular Atrophy Medicine Distributors
  9. 9.2.3 Spinal Muscular Atrophy Medicine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst